Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Classic Hodgkin's Lymphoma

Next Previous
X
Search
Trial Profile

An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Classic Hodgkin's Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Sponsors Jiangsu Hengrui Medicine Co.

    • Most Recent Events

    • 07 Jun 2022 Results of a pooled analysis (NCT03722147, NCT03209973, NCT03155425 and NCT03655483) assessing the survival outcome of patients with relapsed or refractory classical Hodgkin lymphoma who achieved remission during immune checkpoint inhibitors treatment presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 07 Mar 2022 Primary endpoint (ORR assess by IRC) has not been met, according to Results published in the International Journal of Cancer.
    • 07 Mar 2022 Results published in the International Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top